Skip to main content
SpringerLink
Log in

Sarcoidosis

  • Chapter
Pulmonary Arterial Hypertension and Interstitial Lung Diseases

  • 1004 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Baughman RP, du Bois RM, Lower EE. Sarcoidosis. Lancet 2003;361:1111–1118.

    Article  CAS  PubMed  Google Scholar 

  2. Rybicki BA, Major M, Popovich J, Jr., et al. Racial differences in sarcoidosis incidence: a five year study in a health maintenance organization. Am J Epidemiol 1997;145:234–241.

    CAS  PubMed  Google Scholar 

  3. Hillerdal G, Nou E, Osterman K, et al. Sarcoidosis: epidemiology and prognosis. A 15-year European study. Am Rev Respir Dis 1984;130:29–32.

    CAS  PubMed  Google Scholar 

  4. Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001;164:1885–1889.

    CAS  PubMed  Google Scholar 

  5. Judson MA, Baughman RP, Teirstein AS, et al. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. Sarcoidosis Vasc Diffuse Lung Dis 1999;16:75–86.

    CAS  PubMed  Google Scholar 

  6. Pietinalho A, Ohmichi M, Hiraga Y, et al. The mode of presentation of sarcoidosis in Finland and Hokkaido, Japan. A comparative analysis of 571 Finnish and 686 Japanese patients. Sarcoidosis 1996;13:159–166.

    CAS  Google Scholar 

  7. Izumi T. Symposium: population differences in clinical features and prognosis of sarcoidosis throughout the world. Sarcoidosis 1992;9:S105–S118.

    Google Scholar 

  8. Siltzbach LE, James DG, Neville E, et al. Course and prognosis of sarcoidosis around the world. Am J Med 1974;57:847–852.

    Article  CAS  PubMed  Google Scholar 

  9. ACCESS Research Group. Design of a case control etiologic study of sarcoidosis (ACCESS). J Clin Epidemiol 1999;52:1173–1186.

    Article  Google Scholar 

  10. Hills SE, Parkes SA, Baker SB. Epidemiology of sarcoidosis in the Isle of Man—2: Evidence for space-time clustering. Thorax 1987;42:427–430.

    Article  CAS  PubMed  Google Scholar 

  11. Johnson BA, Duncan SR, Ohori NP, et al. Recurrence of sarcoidosis in pulmonary allograft recipients. American Review of Respiratory Disease 1993;148:1373–137X.

    CAS  PubMed  Google Scholar 

  12. Martinez FJ, Orens JB, Deeb M, et al. Recurrence of sarcoidosis following bilateral alloge-neic lung transplantation. Chest 1994;106:1597–1599.

    Article  CAS  PubMed  Google Scholar 

  13. Nunley DR, Hattler B, Keenan RJ, et al. Lung transplantation for end-stage pulmonary sar-coidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999;16:93–100.

    CAS  PubMed  Google Scholar 

  14. Sundar KM, Carveth HJ, Gosselin M V, et al. Granulomatous pneumonitis following bone marrow transplantation. Bone Marrow Transplant 2001;28:627–630.

    Article  CAS  PubMed  Google Scholar 

  15. Heyll A, Meckenstock G, Aul C, et al. Possible transmission of sarcoidosis via allogeneic bone marrow transplantation. Bone Marrow Transplant 1994;14:161–164.

    CAS  PubMed  Google Scholar 

  16. Milman N, Andersen CB, Burton CM, et al. Recurrent sarcoid granulomas in a transplanted lung derive from recipient immune cells. Eur Respir J 2005;26:549–552.

    Article  CAS  PubMed  Google Scholar 

  17. Heatly T, Sekela M, Berger R. Single lung transplantation involving a donor with documented pulmonary sarcoidosis. J Heart Lung Transplant 1994;13:720–723.

    CAS  PubMed  Google Scholar 

  18. Hance AJ. The role of mycobacteria in the pathogenesis of sarcoidosis. Semin Respir Infect 1998;13:197–205.

    CAS  PubMed  Google Scholar 

  19. Drake WP, Pei Z, Pride DT, et al. Molecular analysis of sarcoidosis tissues for mycobacte-rium species DNA. Emerg Infect Dis 2002;8:1334–1341.

    CAS  PubMed  Google Scholar 

  20. Song Z, Marzilli L, Greenlee BM, et al. Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis. J Exp Med 2005;201:755–767.

    Article  CAS  PubMed  Google Scholar 

  21. Drake WP, Dhason MS, Nadaf M, et al. Cellular recognition of Mycobacterium tuberculosis ESAT-6 and KatG peptides in systemic sarcoidosis. Infect Immun 2007;75:527–530.

    Article  CAS  PubMed  Google Scholar 

  22. Brown ST, Brett I, Almenoff PL, et al. Recovery of cell wall-deficient organisms from blood does not distinguish between patients with sarcoidosis and control subjects. Chest 2003;123:413–417.

    Article  PubMed  Google Scholar 

  23. Ishige I, Usui Y, Takemura T, et al. Quantitative PCR of mycobacterial and propionibacterial DNA in lymph nodes of Japanese patients with sarcoidosis. Lancet 1999;354:120–123.

    Article  CAS  PubMed  Google Scholar 

  24. Eishi Y, Suga M, Ishige I, et al. Quantitative analysis of mycobacterial and propionibacterial DNA in lymph nodes of Japanese and European patients with sarcoidosis. J Clin Microbiol 2002;40:198–204.

    Article  CAS  PubMed  Google Scholar 

  25. Minami J, Eishi Y, Ishige Y, et al. Pulmonary granulomas caused experimentally in mice by a recombinant trigger-factor protein of Propionibacterium acnes. J Med Dent Sci 2003;50:265–274.

    PubMed  Google Scholar 

  26. Prezant DJ, Dhala A, Goldstein A, et al. The incidence, prevalence, and severity of sarcoido-sis in New York City firefighters. Chest 1999;116:1183–1193.

    Article  CAS  PubMed  Google Scholar 

  27. Jajosky P. Sarcoidosis diagnoses among U.S. military personnel:trends and ship assignment associations. Am J Prev Med 1998;14(3):176–183.

    Article  CAS  PubMed  Google Scholar 

  28. Gorham ED, Garland CF, Garland FC, et al. Trends and occupational associations in incidence of hospitalized pulmonary sarcoidosis and other lung diseases in Navy personnel:a 27-year historical prospective study, 1975–2001. Chest 2004;126:1431–1438.

    Article  PubMed  Google Scholar 

  29. Drent M, Bomans PH, Van Suylen RJ, et al. Association of man-made mineral fibre exposure and sarcoidlike granulomas. Respir Med 2000;94:815–820.

    Article  CAS  PubMed  Google Scholar 

  30. Newman LS, et al. Etiology of sarcoidosis:environmental and occupational factors associated with sarcoidosis risk. Ann Intern Med 2002; in press.

    Google Scholar 

  31. Izbicki G, Chavko R, Banauch GI, et al. World Trade Center “sarcoid-like” granulomatous pulmonary disease in New York City Fire Department rescue workers. Chest 2007;131:1414–1423.

    Article  PubMed  Google Scholar 

  32. Moller DR, Chen ES. Genetic basis of remitting sarcoidosis:triumph of the trimolecular complex? Am J Respir Cell Mol Biol 2002;27:391–395.

    CAS  PubMed  Google Scholar 

  33. Richeldi L, Sorrentino R, Saltini C. HLA-DPB1 Glutamate 69:a genetic marker of beryllium disease. Science 1993;262:242–244.

    Article  CAS  PubMed  Google Scholar 

  34. Rossman MD, Thompson B, Frederick M, et al. HLA-DRB1*1101:a significant risk factor for sarcoidosis in blacks and whites. Am J Hum Genet 2003;73:720–735.

    Article  CAS  PubMed  Google Scholar 

  35. Sato H, Grutters JC, Pantelidis P, et al. HLA-DQB1*0201:a marker for good prognosis in British and Dutch patients with sarcoidosis. Am J Respir Cell Mol Biol 2002;27:406–412.

    CAS  PubMed  Google Scholar 

  36. Grunewald J, Eklund A. Sex-specific manifestations of Lofgren's syndrome. Am J Respir Crit Care Med 2007;175(1):40–44.

    Article  CAS  PubMed  Google Scholar 

  37. Foley PJ, McGrath DS, Petrek M, et al. HLA-DRB1 position 11 residues are a common protective marker for sarcoidosis. Am J Respir Cell Mol Biol 2001;25:272–277.

    CAS  PubMed  Google Scholar 

  38. Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999;16:149–173.

    CAS  PubMed  Google Scholar 

  39. Teirstein AS, Judson MA, Baughman RP, et al. The spectrum of biopsy sites for the diagnosis of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2005;22:139–146.

    PubMed  Google Scholar 

  40. Judson MA, Thompson BW, Rabin DL, et al. The diagnostic pathway to sarcoidosis. Chest 2003;123:406–412.

    Article  PubMed  Google Scholar 

  41. Winterbauer RH, Belic N, Moores KD. A clinical intepretation of bilateral hilar adenopathy. Ann Intern Med 1973;78:65–71.

    CAS  PubMed  Google Scholar 

  42. Rizzato G, Colombo P. Nephrolithiasis as a presenting feature of chronic sarcoidosis:a prospective study. Sarcoidosis 1996;13:167–172.

    CAS  Google Scholar 

  43. Baughman RP, Judson MA, Teirstein AS, et al. Thalidomide for chronic sarcoidosis. Chest 2002;122:227–232.

    Article  CAS  PubMed  Google Scholar 

  44. Winget D, O'Brien GM, Lower EE, et al. Bell's palsy as an unrecognized presentation for sarcoidosis. Sarcoidosis 1994;11:S368–S370.

    Google Scholar 

  45. Hunninghake GW, Crystal RG. Pulmonary sarcoidosis:a disorder mediated by excess helper T-lymphocyte activity at sites of disease activity. N Engl J Med 1981;305:429–432.

    Article  CAS  PubMed  Google Scholar 

  46. Semenzato G, Chilosi M, Ossi E, et al. Bronchoalveolar lavage and lung histology:comparative analysis of inflammatory and immunocompetent cells in patients with sarcoidosis and hypersensitivity pneumonitis. Am Rev Respir Dis 1985;132:400–404.

    CAS  PubMed  Google Scholar 

  47. Kantrow SP, Meyer KC, Kidd P, et al. The CD4/CD8 ratio in BAL fluid is highly variable in sarcoidosis]. Eur Respir J 1997;10:2716–2721.

    Article  CAS  PubMed  Google Scholar 

  48. Klech H, Pohl W. Technical recommendations and guidelines for bronchoalveolar lavage (BAL). Eur Respir J 1989;2:561–585.

    Google Scholar 

  49. Haslam PL, Baughman RP. ERS task force report on measurement of acellular components in BAL. Eur Resp Rev 1999;9:25–27.

    Google Scholar 

  50. Baughman RP, Drent M. Role of bronchoalveolar lavage in interstitial lung disease. Clin Chest Med 2001;22:331–341.

    Article  CAS  PubMed  Google Scholar 

  51. Poulter LW, Rossi GA, Bjermer L, et al. The value of bronchoalveolar lavage in the diagnosis and prognosis of sarcoidosis. Eur Respir J 1990;3:943–944.

    CAS  PubMed  Google Scholar 

  52. Drent M, Jacobs JA, Cobben NA, et al. Computer program supporting the diagnostic accuracy of cellular BALF analysis:a new release. Respir Med 2001;95:781–786.

    Article  CAS  PubMed  Google Scholar 

  53. Welker L, Jorres RA, Costabel U, et al. Predictive value of BAL cell differentials in the diagnosis of interstitial lung diseases. Eur Respir J 2004;24:1000–1006.

    Article  CAS  PubMed  Google Scholar 

  54. Sugisaki K, Yamaguchi T, Nagai S, et al. Clinical characteristics of 195 Japanese sarcoidosis patients treated with oral corticosteroids. Sarcoidosis Vasc Diffuse Lung Dis 2003;20:222–226.

    PubMed  Google Scholar 

  55. Loddenkemper R, Kloppenborg A, Schoenfeld N, et al. Clinical findings in 715 patients with newly detected pulmonary sarcoidosis—results of a cooperative study in former West Germany and Switzerland. WATL Study Group. Wissenschaftliche Arbeitsgemeinschaft fur die Therapie von Lungenkrankheitan. Sarcoidosis Vasc Diffuse Lung Dis 1998;15:178–182.

    CAS  PubMed  Google Scholar 

  56. Scadding JG. Prognosis of intrathoracic sarcoidosis in England. Br Med J 1961;4:1165–1172.

    Article  Google Scholar 

  57. DeRemee RA. The roentgenographic staging of sarcoidosis. Historic and contemporary perspectives. Chest 1983;83:128–133.

    Article  CAS  PubMed  Google Scholar 

  58. Nagai S, Shigematsu M, Hamada K, et al. Clinical courses and prognoses of pulmonary sarcoidosis. Curr Opin Pulm Med 1999;5:293–298.

    Article  CAS  PubMed  Google Scholar 

  59. Neville E, Walker AN, James DG. Prognostic factors predicting the outcome of sarcoidosis:an analysis of 818 patients. Q J Med 1983;208:525–533.

    Google Scholar 

  60. Koonitz CH, Joyner LR, Nelson RA. Transbronchial lung biopsy via the fiberoptic broncho-scope in sarcoidosis. Ann Intern Med 1976;85:64–66.

    CAS  PubMed  Google Scholar 

  61. Abe S, Munakata M, Nishimura M, et al. Gallium-67 scintigraphy, bronchoalveolar lavage, and pathologic changes in patients with pulmonary sarcoidosis. Chest 1984;85:650–655.

    Article  CAS  PubMed  Google Scholar 

  62. Sulavik SB, Spencer RP, Palestro CJ, et al. Specificity and sensitivity of distinctive chest radiographic and/or 67Ga images in the noninvasive diagnosis of sarcoidosis. Chest 1993; 103:403–409.

    Article  CAS  PubMed  Google Scholar 

  63. Medinger AE, Khouri S, Rohatgi PK. Sarcoidosis:the value of exercise testing. Chest 2001; 120:93–101.

    Article  CAS  PubMed  Google Scholar 

  64. Yeager H, Rossman MD, Baughman RP, et al. Pulmonary and psychosocial findings at enrollment in the ACCESS study. Sarcoidosis Vasc Diffuse Lung Dis 2005;22:147–153.

    PubMed  Google Scholar 

  65. Abehsera M, Valeyre D, Grenier P, et al. Sarcoidosis with pulmonary fibrosis:CT patterns and correlation with pulmonary function. AJR Am J Roentgenol 2000;174:1751–1757.

    CAS  PubMed  Google Scholar 

  66. Terasaki H, Fujimoto K, Muller NL, et al. Pulmonary sarcoidosis:comparison of findings of inspiratory and expiratory high-resolution CT and pulmonary function tests between smokers and nonsmokers. AJR Am J Roentgenol 2005;185:333–338.

    PubMed  Google Scholar 

  67. Hansell DM, Milne DG, Wilsher ML, et al. Pulmonary sarcoidosis:morphologic associations of airflow obstruction at thin-section CT. Radiology 1998;209:697–704.

    CAS  PubMed  Google Scholar 

  68. Baydur A, Alsalek M, Louie SG, et al. Respiratory muscle strength, lung function, and dyspnea in patients with sarcoidosis. Chest 2001;120:102–108.

    Article  CAS  PubMed  Google Scholar 

  69. Brancaleone P, Perez T, Robin S, et al. Clinical impact of inspiratory muscle impairment in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004;21:219–227.

    PubMed  Google Scholar 

  70. Robinson LR, Brownsberger R, Raghu G. Respiratory failure and hypoventilation secondary to neurosarcoidosis. Am J Respir Crit Care Med 1998;157:1316–1318.

    CAS  PubMed  Google Scholar 

  71. Sharma OP, Johnson R. Airway obstruction in sarcoidosis. A study of 123 nonsmoking black American patients with sarcoidosis. Chest 1988;94:343–346.

    Article  CAS  PubMed  Google Scholar 

  72. Ploysongsang Y, Roberts RD. The pathophysiology and response to steroid therapy in sar-coidosis. Respiration 1986;49:204–215.

    Article  CAS  PubMed  Google Scholar 

  73. Chambellan A, Turbie P, Nunes H, et al. Endoluminal stenosis of proximal bronchi in sar-coidosis:bronchoscopy, function, and evolution. Chest 2005;127:472–481.

    Article  PubMed  Google Scholar 

  74. Bechtel JJ, Starr TI, Dantzker DR, et al. Airway hyperreactivity in patients with sarcoidosis. Am Rev Respir Dis 1981;124:759–761.

    CAS  PubMed  Google Scholar 

  75. Olafsson M, Simonsson BG, Hansson SB. Bronchial reactivity in patients with recent pulmonary sarcoidosis. Thorax 1985;40:51–53.

    Article  CAS  PubMed  Google Scholar 

  76. Baughman RP, Iannuzzi MC, Lower EE, et al. Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002;19:198–204.

    PubMed  Google Scholar 

  77. Shorr AF, Torrington KG, Hnatiuk OW. Endobronchial involvement and airway hyperreac-tivity in patients with sarcoidosis. Chest 2001;120:881–886.

    Article  CAS  PubMed  Google Scholar 

  78. Muller NL, Mawson JB, Mathieson JR, et al. Sarcoidosis:correlation of extent of disease at CT with clinical, functional, and radiographic findings. Radiology 1989;171:613–618.

    CAS  PubMed  Google Scholar 

  79. Remy JM, Beuscart R, Sault MC, et al. Subpleural micronodules in diffuse infiltrative lung diseases:evaluation with thin-section CT scans. Radiology 1990;177:133–139.

    PubMed  Google Scholar 

  80. Akkoca O, Celik G, Ulger F, et al. Exercise capacity in sarcoidosis. Study of 29 patients. Med Clin (Barc) 2005;124:686–689.

    Article  Google Scholar 

  81. Delobbe A, Perrault H, Maitre J, et al. Impaired exercise response in sarcoid patients with normal pulmonary functio. Sarcoidosis Vasc Diffuse Lung Dis 2002;19:148–153.

    PubMed  Google Scholar 

  82. Sulica R, Teirstein AS, Kakarla S, et al. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest 2005; 128:1483–1489.

    Article  PubMed  Google Scholar 

  83. Rizzato G, Pezzano A, Sala G, et al. Right heart impairment in sarcoidosis:haemodynamic and echocardiographic study. Eur J Respir Dis 1983;64(2):121–128.

    CAS  PubMed  Google Scholar 

  84. Lama VN, Flaherty KR, Toews GB, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003;168:1084–1090.

    Article  PubMed  Google Scholar 

  85. Baughman RP, Sparkman BK, Lower EE. Six minute walk test and health status assessment in sarcoidosis. Chest 2007;132:207–213.

    Article  PubMed  Google Scholar 

  86. Nunes H, Humbert M, Capron F, et al. Pulmonary hypertension associated with sarcoidosis:mechanisms, haemodynamics and prognosis. Thorax 2006;61:68–74.

    Article  CAS  PubMed  Google Scholar 

  87. Battesti JP, Georges R, Basset F, et al. Chronic cor pulmonale in pulmonary sarcoidosis. Thorax 1978;33:76–84.

    Article  CAS  PubMed  Google Scholar 

  88. Smith LJ, Lawrence JB, Katzenstein AA. Vascular sarcoidosis:a rare cause of pulmonary hypertension. Am J Med Sci 1983;285:38–44.

    Article  CAS  PubMed  Google Scholar 

  89. Hoffstein V, Ranganathan N, Mullen JB. Sarcoidosis simulating pulmonary veno-occlusive disease. Am Rev Respir Dis 1986;134:809–811.

    CAS  PubMed  Google Scholar 

  90. Nunes H, Humbert M, Capron F, et al. Pulmonary hypertension associated with sarcoidosis:mechanisms, haemodynamics and prognosis. Thorax 2006;61:68–74.

    Article  CAS  PubMed  Google Scholar 

  91. Salazar A, Mana J, Sala J, et al. Combined portal and pulmonary hypertension in sarcoidosis. Respiration 1994;61:117–119.

    Article  CAS  PubMed  Google Scholar 

  92. Baughman RP, Engel PJ, Meyer CA, et al. Pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006;23:108–116.

    PubMed  Google Scholar 

  93. Handa T, Nagai S, Miki S, et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 2006;129:1246–1252.

    Article  PubMed  Google Scholar 

  94. Yock PG, Popp RL. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 1984;70:657–662.

    CAS  PubMed  Google Scholar 

  95. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis:a French nationwide prospective multicenter study. Arthritis Rheum 2005;52:3792–3800.

    Article  PubMed  Google Scholar 

  96. Arcasoy SM, Christie JD, Ferrari VA , et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003;167:735–740.

    Article  PubMed  Google Scholar 

  97. Rich S, D'Alonzo GE, Dantzker DR, et al. Magnitude and implications of spontaneous hemodynamic variability in primary pulmonary hypertension. Am J Cardiol 1985;55:159–163.

    Article  CAS  PubMed  Google Scholar 

  98. Arcasoy SM, Christie JD, Pochettino A, et al. Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation. Chest 2001;120:873–880.

    Article  CAS  PubMed  Google Scholar 

  99. Shorr AF, Davies DB, Nathan SD. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest 2003;124:922–928.

    Article  PubMed  Google Scholar 

  100. Shorr AF, Helman DL, Davies DB, et al. Pulmonary hypertension in advanced sarcoidosis:epidemiology and clinical characteristics. Eur Respir J 2005;25:783–788.

    Article  CAS  PubMed  Google Scholar 

  101. Fahy GJ, Marwick T, McCreery CJ, et al. Doppler echocardiographic detection of left ventricular diastolic dysfunction in patients with pulmonary sarcoidosis. Chest 1996;109:62–66.

    Article  CAS  PubMed  Google Scholar 

  102. Chapelon-Abric C, de ZD, Duhaut P, et al. Cardiac sarcoidosis:a retrospective study of 41 cases. Medicine (Baltimore) 2004;83:315–334.

    Article  Google Scholar 

  103. Baughman RP, Engel PJ. Not all pulmonary hypertension in sarcoidosis is due to pulmonary arterial hypertension. 2007:in press.

    Google Scholar 

  104. Maddrey WC, Johns CJ, Boitnott JK. et al. Sarcoidosis and chronic hepatic disease:a clinical and pathologic study of 20 patients. Medicine 1970;49:375–395.

    Article  CAS  PubMed  Google Scholar 

  105. Judson MA. Hepatc, splenic, and gastrointestinal involvement with sarcoidosis. Sem Resp Crit Care Med 2002;23:529–543.

    Article  Google Scholar 

  106. Baughman RP, Selroos O. Evidence-based approach to the treatment of sarcoidosis. In:Gibson PG, Abramson M, Wood-Baker R, et al,, editors. Evidence-based respiratory medicine. Malden:Blackwell Publishing Ltd.; 2005. p. 491–508.

    Chapter  Google Scholar 

  107. Hunninghake GW, Gilbert S, Pueringer R, et al. Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med 1994;149:893–898.

    CAS  PubMed  Google Scholar 

  108. Gottlieb JE, Israel HL, Steiner RM, et al. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest 1997;111:623–631.

    CAS  Google Scholar 

  109. Rizzato G, Montemurro L, Colombo P. The late follow-up of chronic sarcoid patients previously treated with corticosteroids. Sarcoidosis 1998;15:52–58.

    CAS  Google Scholar 

  110. Baughman RP, Judson MA, Teirstein A, et al. Presenting characteristics as predictors of duration of treatment in sarcoidosis. QJM 2006;99:307–315.

    Article  CAS  PubMed  Google Scholar 

  111. Paramothayan S, Jones PW. Corticosteroid therapy in pulmonary sarcoidosis:a systematic review. JAMA 2002;287:1301–1307.

    Article  CAS  PubMed  Google Scholar 

  112. Pietinalho A, Lindholm A, Haahtela T, et al. Inhaled budesonide for treatment of pulmonary sarcoidosis. Results of a double-blind, placebo-controlled, multicentre study. Eur Respir J 1996;9(suppl 23):406s.

    Google Scholar 

  113. Pietinalho A, Tukiainen P, Haahtela T, et al. Early treatment of stage II sarcoidosis improves 5-year pulmonary function. Chest 2002;121:24–31.

    Article  PubMed  Google Scholar 

  114. Gibson GJ, Prescott RJ, Muers MF, et al. British Thoracic Society Sarcoidosis study:effects of long term corticosteroid treatment. Thorax 1996;51:238–247.

    Article  CAS  PubMed  Google Scholar 

  115. Judson MA. An approach to the treatment of pulmonary sarcoidosis with corticosteroids:the six phases of treatment. Chest 1999;115:1158–1165.

    Article  CAS  PubMed  Google Scholar 

  116. Paramothayan S, Lasserson T, Walters EH. Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis. Cochrane Database Syst Rev 2003;(3):CD003536.

    Google Scholar 

  117. British Tuberculosis Association. Chloroquine in the treatment of sarcoidosis. Tubercle 1967;48:257–272.

    Article  Google Scholar 

  118. Siltzbach LE, Teirstein AS. Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis. Acta Med Scand 1964;425:302S-308S.

    Google Scholar 

  119. Zic J, Horowitz D, Arzubiaga C, et al. Treatment of cutaneous sarcoidosis with chloroquine:review of the literature. Arch Dermatol 1991;127:1034–1040.

    Article  CAS  PubMed  Google Scholar 

  120. Baltzan M, Mehta S, Kirkham TH, et al. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med 1999;160:192–197.

    CAS  PubMed  Google Scholar 

  121. Jones E, Callen JP. Hydroxychloroquine is effective therapy for control of cutaneous sarcoi-dal granulomas. J Am Acad Dermatol 1990;23:487–489.

    Article  CAS  PubMed  Google Scholar 

  122. Canadian Consensus Conference on hydroxychloroquine. J Rheumatol 2000;27:2919–2921.

    Google Scholar 

  123. Bartel PR, Roux P, Robinson E, et al. Visual function and long-term chloroquine treatment. South African Med J 1994;84:32–34.

    CAS  Google Scholar 

  124. Silman A, Shipley M. Ophthalmological monitoring for hydroxychloroquine toxicity:a scientific review of available data. Br J Rheumatol 1997;36:599–601.

    Article  CAS  PubMed  Google Scholar 

  125. Adams JS, Diz MM, Sharma OP. Effective reduction in the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia with short-course chlo-roquine therapy. Ann Intern Med 1989;111:437–438.

    CAS  PubMed  Google Scholar 

  126. Barre PE, Gascon-Barre M, Meakins JL, et al. Hydroxychloroquine treatment of hypercal-cemia in a patient with sarcoidosis undergoing hemodialysis. Am J Med 1987;82:1259–1262.

    Article  CAS  PubMed  Google Scholar 

  127. O'Leary TJ, Jones G, Yip A, et al. The effects of chloroquine on serum 1,25-dihydroxyvita-min D and calcium metabolism in sarcoidosis. N Engl J Med 1986;315:727–730.

    Article  PubMed  Google Scholar 

  128. Sharma OP. Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurologic involvement. Arch Neurol 1998;55:1248–1254.

    Article  CAS  PubMed  Google Scholar 

  129. Baughman RP, Lower EE. A clinical approach to the use of methotrexate for sarcoidosis. Thorax 1999;54:742–746.

    Article  CAS  PubMed  Google Scholar 

  130. Dev S, McCallum RM, Jaffe GJ. Methotrexate for sarcoid-associated panuveitis. Ophthalmology 1999;106:111–118.

    Article  CAS  PubMed  Google Scholar 

  131. Lacher MJ. Spontaneous remission response to methotrexate in sarcoidosis. Ann Intern Med 1968;69:1247–1248.

    CAS  PubMed  Google Scholar 

  132. Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 1995;155:846–851.

    Article  CAS  PubMed  Google Scholar 

  133. Vucinic VM. What is the future of methotrexate in sarcoidosis? A study and review. Curr Opin Pulm Med 2002;8:470–476.

    Article  PubMed  Google Scholar 

  134. Webster GF, Razsi LK, Sanchez M, et al. Weekly low-dose methotrexate therapy for cutaneous sarcoidosis. J Am Acad Dermatol 1991;24:451–454.

    Article  CAS  PubMed  Google Scholar 

  135. Lower EE, Broderick JP, Brott TG, et al. Diagnosis and management of neurologic sarcoido-sis. Arch Intern Med 1997;157:1864–1868.

    Article  CAS  PubMed  Google Scholar 

  136. Gedalia A, Molina JF, Ellis GS, et al. Low-dose methotrexate therapy for childhood sar-coidosis. J Pediatr 1997;130:25–29.

    Article  CAS  PubMed  Google Scholar 

  137. Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis:results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 2000;17:60–66.

    CAS  PubMed  Google Scholar 

  138. Lower EE, Smith JT, Martelo OJ, et al. The anemia of sarcoidosis. Sarcoidosis 1988;5:51–55.

    CAS  PubMed  Google Scholar 

  139. Browne PM, Sharma OP, Salkin D. Bone marrow sarcoidosis. JAMA 1978;240:43–50.

    Article  Google Scholar 

  140. Baughman RP, Koehler A, Bejarano PA, et al. Role of liver function tests in detecting methotrexate-induced liver damage in sarcoidosis. Arch Intern Med 2003;163:615–620.

    Article  CAS  PubMed  Google Scholar 

  141. Kremer JM, Alarcon GS, Lightfoot RW, Jr., et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994;37:316–328.

    CAS  Google Scholar 

  142. Kremer JM, Alarcon GS, Weinblatt ME, et al. Clinical, laboratory, radiographic, and his-topathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis:a multicenter study with literature review. Arthritis Rheum 1997;40:1829–1837.

    Article  CAS  PubMed  Google Scholar 

  143. Zisman DA, McCune WJ, Tino G, et al. Drug-induced pneumonitis:the role of methotrex-ate. Sarcoidosis Vasc Diffuse Lung Dis 2001;18:243–252.

    CAS  PubMed  Google Scholar 

  144. Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004;21:43–48.

    PubMed  Google Scholar 

  145. Lewis SJ, Ainslie GM, Bateman ED. Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999;16:87–92.

    CAS  PubMed  Google Scholar 

  146. Muller-Quernheim J, Kienast K, Held M, et al. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J 1999;14:1117–1122.

    Article  CAS  PubMed  Google Scholar 

  147. Agbogu BN, Stern BJ, Sewell C, et al. Therapeutic considerations in patients with refractory neurosarcoidosis. Arch Neurol 1995;52:875–879.

    CAS  PubMed  Google Scholar 

  148. Kennedy PT, Zakaria N, Modawi SB, et al. Natural history of hepatic sarcoidosis and its response to treatment. Eur J Gastroenterol Hepatol 2006;18:721–726.

    Article  CAS  PubMed  Google Scholar 

  149. Escousse A, Mousson C, Santona L, et al. Azathioprine-induced pancytopenia in homogenous thioprine methyltransferase-deficient renal transplant recipients:a family study. Transplant Proc 1995;27:1739–1742.

    CAS  PubMed  Google Scholar 

  150. Kremer JM, Genovese MC, Cannon GW, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137:726–733.

    CAS  PubMed  Google Scholar 

  151. Kremer JM, Caldwell JR, Cannon GW, et al. The combination of leflunomide and meth-otrexate in patients with active rheumatoid arthritis who are failing on methotrexate treatment alone:a double-blind placebo controlled study. 2000:S224.

    Google Scholar 

  152. Osiri M, Shea B, Robinson V, et al. Leflunomide for the treatment of rheumatoid arthritis:a systematic review and metaanalysis. J Rheumatol 2003;30:1182–1190.

    CAS  PubMed  Google Scholar 

  153. Israel HL, McComb BL. Chlorambucil treatment of sarcoidosis. Sarcoidosis 1991;8:35–41.

    CAS  PubMed  Google Scholar 

  154. Kataria YP. Chlorambucil in sarcoidosis. Chest 1980;78:36–42.

    Article  CAS  PubMed  Google Scholar 

  155. Doty JD, Mazur JE, Judson MA. Treatment of corticosteroid-resistant neurosarcoidosis with a short-course cyclophosphamide regimen. Chest 2003;124:2023–2026.

    Article  PubMed  Google Scholar 

  156. Baughman RP, Lower EE. Use of intermittent, intravenous cyclophosphamide for idiopathic pulmonary fibrosis. Chest 1992;102:1090–1094.

    Article  CAS  PubMed  Google Scholar 

  157. Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996;124:477–484.

    CAS  PubMed  Google Scholar 

  158. Bradley DA, Lower EE, Baughman RP. Diagnosis and management of spinal cord sarcoido-sis. Sarcoidosis Vasc Diffuse Lung Dis 2006;23(1):58–65.

    PubMed  Google Scholar 

  159. Rosenbaum JT. Treatment of severe refractory uveitis with intravenous cyclophosphamide. J Rheumatol 1994;21:123–125.

    CAS  PubMed  Google Scholar 

  160. Zuber M, Defer G, Cesaro P, et al. Efficacy of cyclophosphamide in sarcoid radiculomyelitis. J Neurol Neurosurg Psychiatry 1992;55:166–167.

    Article  CAS  PubMed  Google Scholar 

  161. Carlesimo M, Giustini S, Rossi A, et al. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995;32:866–869.

    Article  CAS  PubMed  Google Scholar 

  162. Lee JB, Koblenzer PS. Disfiguring cutaneous manifestation of sarcoidosis treated with tha-lidomide:a case report. J Am Acad Dermatol 1998;39:835–838.

    Article  CAS  PubMed  Google Scholar 

  163. Nguyen YT, Dupuy A, Cordoliani F, et al. Treatment of cutaneous sarcoidosis with thalido-mide. J Am Acad Dermatol 2004;50:235–241.

    Article  PubMed  Google Scholar 

  164. Oliver SJ, Kikuchi T, Krueger JG, et al. Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement. Clin Immunol 2002;102:225–236.

    Article  CAS  PubMed  Google Scholar 

  165. Rousseau L, Beylot-Barry M, Doutre MS, et al. Cutaneous sarcoidosis successfully treated with low doses of thalidomide. Arch Dermatol 1998;134:1045–1046.

    Article  CAS  PubMed  Google Scholar 

  166. Judson MA, Silvestri J, Hartung C, et al. The effect of thalidomide on corticosteroid-depend-ent pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006;23:51–57.

    PubMed  Google Scholar 

  167. Baughman RP, Strohofer SA, Buchsbaum J, et al. Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. J Lab Clin Med 1990;115:36–42.

    CAS  PubMed  Google Scholar 

  168. Ziegenhagen MW, Benner UK, Zissel G, et al. Sarcoidosis:TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers. Am J Respir Crit Care Med 1997;156:1586–1592.

    CAS  PubMed  Google Scholar 

  169. Baughman RP, Lower EE. The effect of corticosteroid or methotrexate therapy on lung lymphocytes and macrophages in sarcoidosis. Am Rev Respir Dis 1990;142:1268–1271.

    CAS  PubMed  Google Scholar 

  170. Ziegenhagen MW, Rothe E, Zissel G, et al. Exagerated TNFalpha release of alveolar macrophages in corticosteroid resistant sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002;19:185–190.

    PubMed  Google Scholar 

  171. Baughman RP, Iannuzzi M. Tumour necrosis factor in sarcoidosis and its potential for targeted therapy. BioDrugs 2003;17:425–431.

    Article  CAS  PubMed  Google Scholar 

  172. Gartlehner G, Hansen RA, Jonas BL, et al. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis:a systematic review and metaanalysis. J Rheumatol 2006;33:2398–2408.

    CAS  PubMed  Google Scholar 

  173. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763–769.

    Article  CAS  PubMed  Google Scholar 

  174. Kavanaugh A, Clair EW, McCune WJ, et al. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol 2000;27:841–850.

    CAS  PubMed  Google Scholar 

  175. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876–885.

    Article  CAS  PubMed  Google Scholar 

  176. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease:a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;121:1088–1094.

    Article  CAS  PubMed  Google Scholar 

  177. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor-alpha neutralizing agent. N Engl J Med 2001;345:1098–1104.

    Article  CAS  PubMed  Google Scholar 

  178. Baughman RP, Bradley DA, Lower EE. Infliximab for chronic ocular inflammation. Int J Clin Pharmacol Ther 2005;43:7–11.

    CAS  PubMed  Google Scholar 

  179. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001;18:70–74.

    CAS  PubMed  Google Scholar 

  180. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest 2005; 127:1064–1071.

    Article  CAS  PubMed  Google Scholar 

  181. Saleh S, Ghodsian S, Yakimova V, et al. Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir Med 2006;100(11):2053–2059.

    Article  PubMed  Google Scholar 

  182. Yee AMF, Pochapin MB. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis-alpha therapy. Ann Intern Med 2001;135:27–31.

    CAS  PubMed  Google Scholar 

  183. Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sar-coidosis and pulmonary involvement. Am J Respir Crit Care Med 2006;174:795–802.

    Article  CAS  PubMed  Google Scholar 

  184. Hanauer SB. Review article:safety of infliximab in clinical trials. Alimentary Pharm Therapeutics 1999;13(Suppl 4):16–22.

    Article  CAS  Google Scholar 

  185. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure:results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133–3140.

    Article  CAS  PubMed  Google Scholar 

  186. Utz JP, Limper AH, Kalra S, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003;124:177–185.

    Article  CAS  PubMed  Google Scholar 

  187. Baughman RP, Lower EE, Bradley DA, et al. Etanercept for refractory ocular sarcoidosis:results of a double-blind randomized trial. Chest 2005;128:1062–1067.

    Article  PubMed  Google Scholar 

  188. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure:results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004;109:1594–1602.

    Article  CAS  PubMed  Google Scholar 

  189. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005;352:351–361.

    Article  Google Scholar 

  190. Wallis RS, Ehlers S. Tumor necrosis factor and granuloma biology:explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum 2005;34(5 Suppl 1):34–38.

    Article  CAS  PubMed  Google Scholar 

  191. Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastro-enterology 2003;124:1774–1785.

    Article  CAS  Google Scholar 

  192. Bachelez H, Senet P, Cadranel J, et al. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol 2001;137:69–73.

    CAS  PubMed  Google Scholar 

  193. Breuer K, Gutzmer R, Volker B, et al. Therapy of noninfectious granulomatous skin diseases with fumaric acid esters. Br J Dermatol 2005;152:1290–1295.

    Article  CAS  PubMed  Google Scholar 

  194. Zabel P, Entzian P, Dalhoff K, et al. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med 1997;155:1665–1669.

    CAS  PubMed  Google Scholar 

  195. Marques LJ, Zheng L, Poulakis N, et al. Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. Am J Respir Crit Care Med 1999;159(2):508–511.

    CAS  PubMed  Google Scholar 

  196. Strieter RM, Remick DG, Ward PA, et al. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun 1988;155:1230–1236.

    Article  CAS  PubMed  Google Scholar 

  197. Judson MA. Lung transplantation for pulmonary sarcoidosis. Eur Respir J 1998;11:738–744.

    CAS  PubMed  Google Scholar 

  198. Preston IR, Klinger JR, Landzberg MJ, et al. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest 2001;120:866–872.

    Article  CAS  PubMed  Google Scholar 

  199. Fisher KA, Serlin DM, Wilson KC, et al. Sarcoidosis-associated pulmonary hypertension:outcome with long-term epoprostenol treatment. Chest 2006;130:1481–1488.

    Article  CAS  PubMed  Google Scholar 

  200. Foley RJ, Metersky ML. Successful Treatment of Sarcoidosis-Associated Pulmonary Hypertension with Bosentan. Respiration 2008;75:211–214.

    Article  CAS  PubMed  Google Scholar 

  201. Sharma S, Kashour T, Philipp R. Secondary pulmonary arterial hypertension:treated with endothelin receptor blockade. Tex Heart Inst J 2005;32:405–410.

    PubMed  Google Scholar 

  202. Letizia C, Danese A, Reale MG, et al. Plasma levels of endothelin-1 increase in patients with sarcoidosis and fall after disease remission. Panminerva Med 2001;43:257–261.

    CAS  PubMed  Google Scholar 

  203. Terashita K, Kato S, Sata M, et al. Increased endothelin-1 levels of BAL fluid in patients with pulmonary sarcoidosis. Respirology 2006;11:145–151.

    Article  PubMed  Google Scholar 

  204. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148–2157.

    Article  CAS  PubMed  Google Scholar 

  205. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension:a randomised controlled trial. Lancet 2002;360:895–900.

    Article  CAS  PubMed  Google Scholar 

  206. Collard HR, Anstrom KJ, Schwarz MI, et al. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 2007;131:897–899.

    Article  PubMed  Google Scholar 

  207. Milman N, Burton CM, Iversen M, et al. Pulmonary hypertension in end-stage pulmonary sarcoidosis:therapeutic effect of sildenafil? J Heart Lung Transplant 2008;27:329–334.

    Article  PubMed  Google Scholar 

  208. Pietinalho A, Ohmichi M, Lofroos AB, et al. The prognosis of sarcoidosis in Finland and Hokkaido, Japan. A comparative five-year study of biopsy-proven cases. Sarcoidosis Vasc Diffuse Lung Dis 2000;17:158–166.

    CAS  PubMed  Google Scholar 

  209. Baughman RP, Lower EE. Therapy for sarcoidosis. Eur Respir Mon 2005;32:301–315.

    Article  Google Scholar 

  210. Baughman RP, Sparkman BK, Lower EE. Six-minute walk test and health status assessment in sarcoidosis. Chest 2007;132:207–213.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Cincinnati Medical Center, Cincinnati, OH

    Robert P. Baughman & Elyse E. Lower

  2. Ohio Heart and Vascular Center, Cincinnati, OH

    Peter Engel

Authors
  1. Robert P. Baughman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elyse E. Lower
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Engel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Internal Medicine, University of Cincinnati, Cincinnati, OH

    Robert P. Baughman

  2. Department of Internal Medicine, Regional Hospital, Aosta, Italy

    Roberto G. Carbone  & Giovanni Bottino  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Baughman, R.P., Lower, E.E., Engel, P. (2009). Sarcoidosis. In: Baughman, R.P., Carbone, R.G., Bottino, G. (eds) Pulmonary Arterial Hypertension and Interstitial Lung Diseases. Humana Press. https://doi.org/10.1007/978-1-60327-074-8_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-074-8_11

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-695-5

  • Online ISBN: 978-1-60327-074-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation